Small cell carcinoma of the prostate (Q38188869)

30 August 2017

Small cell carcinoma of the prostate (English)

1 reference

30 August 2017

1 reference

4

Jonathan I Epstein

1 reference

30 August 2017

Rosa Nadal

1

1 reference

30 August 2017

Michael Schweizer

series ordinal

2

1 reference

30 August 2017

Oleksandr N Kryvenko

series ordinal

3

1 reference

30 August 2017

Mario A Eisenberger

series ordinal

5

1 reference

30 August 2017

language of work or name

English

0 references

publication date

18 February 2014

1 reference

30 August 2017

Nature Reviews Urology

1 reference

30 August 2017

11

1 reference

30 August 2017

213-219

1 reference

30 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/nrurol.2014.21

30 August 2017

0 references

cites work

Platinum-based chemotherapy for variant castrate-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Modeling a lethal prostate cancer variant with small-cell carcinoma features

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Mitosis as an anti-cancer target

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Immunohistochemical analysis of neuroendocrine differentiation in prostate cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Unusual and underappreciated: small cell carcinoma of the prostate.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Neuroendocrine differentiation in prostate cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Small cell carcinoma of the prostate: an immunohistochemical study.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Molecular characterization of prostatic small-cell neuroendocrine carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Neuroendocrine cells in tumour growth of the prostate

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Brain metastasis from prostate carcinoma: antemortem recognition and outcome after treatment

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Neuroendocrine differentiation in prostatic carcinomas: histogenesis, biology, clinical relevance, and future therapeutical perspectives

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Small cell carcinoma of prostate: Effectiveness of hormonal versus chemotherapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

The diffuse endocrine system and the implications of the APUD concept

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Survival of patients with small cell carcinoma of the prostate during 1973-2003: a population-based study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Prostatic adenocarcinoma evolving into carcinoid: selective effect of hormonal treatment?

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer?

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Ectopic ACTH, prostatic oat cell carcinoma, and marked hypernatremia

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Neuroendocrine differentiation in prostatic malignancy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Pathologic results of radical prostatectomies in patients with simultaneous atypical small acinar proliferation and prostate cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

ERG gene rearrangements are common in prostatic small cell carcinomas

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Small cell anaplastic carcinoma of the prostate: seven new cases, review of the literature, and discussion of a therapeutic strategy

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Neuro-endocrine cells--a new prognostic parameter in prostate cancer

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Small cell carcinoma of the prostate

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Chemotherapy for Small Cell Carcinoma of Prostatic Origin

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Neuroendocrine tumor cells in prostate cancer: evaluation of the neurosecretory products serotonin, bombesin, and gastrin - impact on angiogenesis and clinical follow-up

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

ERG rearrangement in small cell prostatic and lung cancer

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Unusual cause of ectopic secretion of adrenocorticotropic hormone: Cushing syndrome attributable to small cell prostate cancer

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Serum chromogranin-A in advanced prostate cancer

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4339095

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

31 August 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.21

Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.21

Small Cell (Neuroendocrine) Carcinoma of the Prostate: Etiology, Diagnosis, Prognosis, and Therapeutic Implications—A Retrospective Study of 30 Patients From the Rare Cancer Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.21

Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.21

Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.21

Prostate cancer and neuroendocrine differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.21

Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.21

Neuroendocrine differentiation in metastatic prostatic adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.21

Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.21

Progression of prostate cancer to neuroendocrine cell tumor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.21

Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.21

Small cell carcinoma of the prostate. II. Immunohistochemical and electron microscopic studies of 18 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.21

Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.21

Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.21

Large Cell Neuroendocrine Carcinoma of Prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.21

Small Cell Anaplastic Carcinoma of the Prostate: A Clinical, Pathological and Immunohistological Study of 27 Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.21

Treatment outcomes of small cell carcinoma of the prostate: a single-center study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.21

Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.21

Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.21

Small-cell carcinoma of prostate. Transient complete remission with chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.21

Primary small cell carcinoma of the prostate: unusual modes of presentation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2014.21

31 March 2020

Identifiers

DOI

10.1038/NRUROL.2014.21

1 reference

Dimensions Publication ID

30 August 2017

0 references

1 reference

30 August 2017

1 reference